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Abstract The concept of chronic critical limb ischaemia (CLI) emerged late in the history
of peripheral arterial occlusive disease (PAOD). The historical background and changing
deﬁnitions of CLI over the last decades are important to know in order to understand
why epidemiologic data are so difﬁcult to compare between articles and over time.
The prevalence of CLI is probably very high and largely underestimated, and signiﬁcant
differences exist between population studies and clinical series. The extremely high costs
associated with management of these patients make CLI a real public health issue for the
future. In the era of emerging vascular surgery in the 1950s, the initial classiﬁcation of
PAOD by Fontaine, with stages III and IV corresponding to CLI, was based only on clinical
symptoms. Later, with increasing access to non-invasive haemodynamic measurements
(ankle pressure, toe pressure), the need to prove a causal relationship between PAOD and
clinical ﬁndings suggestive of CLI became a real concern, and the Rutherford classiﬁcation
published in 1986 included objective haemodynamic criteria. The ﬁrst consensus document
on CLI was published in 1991 and included clinical criteria associated with ankle and toe
pressure and transcutaneous oxygen pressure (TcPO2) cut-off levels (50mmHg, 30mmHg
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and 10mmHg respectively). This rigorous deﬁnition reﬂects an arterial insufﬁciency
that is so severe as to cause microcirculatory changes and compromise tissue integrity,
with a high rate of major amputation and mortality. The TASC I consensus document
published in 2000 used less severe pressure cut-offs (<50––70mmHg, <30––50mmHg and
<30––50mmHg respectively). The thresholds for toe pressure and especially TcPO2 (which
will be also included in TASC II consensus document) are however just below the lower
limit of normality. It is therefore easy to infer that patients qualifying as CLI based on
TASC criteria can suffer from far less severe disease than those qualifying as CLI in the initial
1991 consensus document. Furthermore, inclusion criteria of many recent interventional
studies have even shifted further from the efforts of deﬁnition standardisation with
objective criteria, by including patients as CLI based merely on Fontaine classiﬁcation
(stage III and IV) without haemodynamic criteria. The differences in the natural history
of patients with CLI, including prognosis of the limb and the patient, are thus difﬁcult
to compare between studies in this context. Overall, CLI as deﬁned by clinical and
haemodynamic criteria remains a severe condition with poor prognosis, high medical costs
and a major impact in terms of public health and patients’ loss of functional capacity.
The major progresses in best medical therapy of arterial disease and revascularisation
procedures will certainly improve the outcome of CLI patients. In the future, an effort
to apply a standardised deﬁnition with clinical and objective haemodynamic criteria
will be needed to better demonstrate and compare the advances in management of
these patients.
© 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
1. Introduction
The concept of chronic critical limb ischaemia (hereafter
referred to as CLI) emerged late in the history of peripheral
arterial occlusive disease (PAOD). It refers to a state of
arterial insufﬁciency that reduces distal perfusion pressure
to such an extent that microcirculation and nutrient
blood ﬂow to tissues are severely disturbed. Much of the
interest in CLI originally focused on deﬁning an accurate and
objective description of patients that could allow a thorough
comparison between various treatment modalities. Indeed,
early in the history of CLI, a true need for greater objectivity
in characterising patients undergoing surgical procedures
was felt, with the aim of getting rid of subjective terms
such as “limb-threatening ischaemia” and “limb salvage
operations”. Later, such standardisation was also judged
necessary to deﬁne patients in non-surgical management
trials.
This review ﬁrst presents the historical background of
CLI and its evolving deﬁnitions over time, as well as the
available epidemiologic data. Then, the hallmarks of CLI
clinical presentation are described, with an emphasis on
the need for objective haemodynamic conﬁrmation of the
causal link between PAOD and clinical ﬁndings. Finally, the
prognosis of CLI is discussed as well as some risk stratiﬁcation
tools.
2. Historical background
In 1952, during the ﬁrst meeting of the European Society
for Cardiovascular Surgery dedicated to aorto-iliac lesions,
Fontaine et al. introduced a simple clinical classiﬁcation of
patients with chronic arterial disease of lower limbs (LL) in
four stages.1 At that time, vascular surgery was emerging
and patients used to present with advanced disease often
associated with obvious symptoms and signs of chronic
severe ischaemia. Moreover, haemodynamic measurements
were almost non-existent (the ﬁrst demonstration of a fall
in ankle pressure in PAOD was made by Windsor in 1950), so
that Fontaine’s classiﬁcation implied a causal link between
the symptoms and signs and PAOD. Unfortunately, Fontaine’s
classiﬁcation is nowadays too often used as “(any) rest pain +
PAOD = PAOD stage III” or “(any) ulceration or gangrene +
PAOD = PAOD stage IV”, regardless of the actual severity of
PAOD.
In 1969, Yao introduced measurement of the ankle-
brachial pressure index (ABI) with a 10MHz Doppler probe,
and demonstrated a pressure drop proportional to the
severity of occlusive lesions.2 Yao also showed signiﬁcant
differences in ABI ranges across Fontaine stages, despite
some overlap between stages II and III, and stages III and IV.3
However, only patients with proximal (iliac or femoro-
popliteal) lesions were included, thus excluding a signiﬁcant
number of patients with leg artery calciﬁcation. At the
same period, the accuracy of toe pressure for quantiﬁcation
of arterial insufﬁciency in PAOD was demonstrated by
Carter et al.4
The expression “critical ischaemia” appeared in 1982 in
the literature to describe LL ischaemia of such severity
that major amputation became necessary in the absence
of successful revascularisation.5 This deﬁnition included
an absolute ankle systolic pressure <40mmHg in case of
rest pain and <60mmHg in case of ulcer or gangrene.
Nevertheless, it soon appeared that ankle pressure was
inadequate in case of ulcer or gangrene, toe pressure being
a better predictor of foot viability particularly in diabetic
patients, and that an evaluation of skin perfusion could be
useful.6,7
In 1986, the First Society for Vascular Surgery/
International Society for CardioVascular Surgery (SVS/ISCVS)
Standards for reports dealing with lower extremity ischaemia
were published,8 including a recommendation for staging
chronic limb ischaemia that would become known as the
Rutherford classiﬁcation. This classiﬁcation is similar to
Fontaine’s classiﬁcation, but its originality lies in adding an
objective criterion to each clinical category: resting ankle
pressure <40mmHg/ﬂat or barely pulsatile forefoot pulse
volume recording/toe pressure <30mmHg for ischaemic
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rest pain (Grade II, Category 4); resting ankle pressure
<60mmHg/ﬂat or barely pulsatile forefoot pulse volume
recording/toe pressure <30mmHg for minor (Grade III,
Category 5) or major (Grade III, Category 6) tissue loss.
All these criteria remained unchanged in the 1997 revised
version of SVS/ISCVS Standards for reports dealing with lower
extremity ischaemia.9 Unfortunately, in the Trans-Atlantic
Inter-Society Consensus (TASC) Document on Management
of Peripheral Arterial Disease10 and thereafter, only the
clinical description of Rutherford categories are maintained,
and Rutherford classiﬁcation as often used nowadays has
lost what made its strength compared to Fontaine’s
classiﬁcation.
Of note, Fontaine and Rutherford classiﬁcations were
suggested by individual physicians. The ﬁrst experts’
consensus document on CLI was published in April 1991
after the Second European Meeting on Chronic Critical
Leg Ischemia,11,12 followed by TASC I and II consensus
documents.10,13
These different suggested deﬁnitions of CLI are discussed
in detail in the following section, but this historical reminder
seemed important to us. Indeed, when reading many recent
articles, one can wonder if the original purpose of creating
the term CLI with a rigorous and objective deﬁnition has not
been somewhat forgotten.
3. Deﬁnitions of chronic critical limb
ischaemia
CLI represents the end stage of PAOD, in which macrovas-
cular lesions induce such a reduction of distal perfusion
pressure that microcirculation and nutrient blood ﬂow to the
tissues are severely disturbed. It is important to emphasise
that the deﬁnition of CLI has evolved over time, from
the initial document of 1991 to TASC I and II consensus
documents published more recently. These three deﬁnitions
are presented and commented on below. The concept of
chronic subcritical limb ischaemia is also brieﬂy discussed at
the end of this section.
3.1. Second European Meeting Consensus document on CLI
(1991)11
This document includes two levels of CLI deﬁnition
reproduced below as they appear in the original version: one
for clinical use in daily practice, and the second for clinical
research and publications.
Recommendation 1
CLI, in both diabetic and non-diabetic patients, is deﬁned
by either of the following two criteria:
• persistently recurring ischemic rest pain requiring regular
adequate analgesia for more than two weeks with an
ankle systolic pressure 50mmHg and/or toe systolic
pressure 30mmHg;
• ulceration or gangrene of the foot or toes, with an
ankle systolic pressure 50mmHg or toe systolic pressure
30mmHg.
Of note, the terms rest pain, ulceration or gangrene should
be applied according to the classical description of ischaemic
rest pain and trophic changes (see section 5 on clinical
presentation of CLI).
Recommendation 2
A more precise description of the type and severity of CLI is
also necessary for the design and reporting of clinical trials.
In addition to the above deﬁnition (Recommendation 1), the
following information is also desirable:
• arteriography to delineate the anatomy of the large
vessel disease throughout the leg and foot;
• toe arterial pressure in all patients, including those
who are not diabetic;
• a technique for quantifying the local microcirculation
in the ischemic area [e.g. capillary microscopy, transcuta-
neous oxygen pressure (TcPO2), or laser Doppler].
Of note, TcPO2 is usually 10mmHg in supine position
in CLI patients and is not increased with inhalation of
oxygen; further sensitivity may be obtained by performing
the measurements in sitting position.
Soon after its publication, this deﬁnition was criticised,
mainly because an ankle pressure threshold of 50mmHg
was judged too low. Furthermore, the true interest of
ankle pressure was questioned, particularly in diabetic
patients.12,14 Nevertheless, these criteria seemed well
accepted by vascular surgeons, as demonstrated by a
computer-interactive voting session during the European
Society for Vascular Surgery (ESVS) meeting in Barcelona
in 1993. Among 158 participants, of whom 82% were
vascular surgeons, 83% agreed on either ankle pressure
50mmHg (55%) or toe pressure 30mmHg (28%), and
12% preferred to add a microcirculatory parameter to
deﬁne CLI.15
3.2. Trans-Atlantic Inter-Society Consensus (TASC)
Document on Management of Peripheral Arterial
Disease (2000)10
This document includes the following recommendations
concerning CLI.
Recommendation 73 Clinical deﬁnition of critical limb
ischemia (CLI)
The term critical limb ischemia should be used for
all patients with chronic ischemic rest pain, ulcers,
or gangrene attributable to objectively proven arterial
occlusive disease. The CLI implies chronicity and is to be
distinguished from acute limb ischemia.
Recommendation 74 Trials and reporting standards deﬁni-
tion of CLI
A relatively inclusive entry criterion is favoured, the aim
being to ensure that the ulceration, gangrene, or rest pain
is indeed caused by peripheral arterial disease and that
most would be expected to require a major amputation
within the next 6 months to a year in the absence
of a signiﬁcant haemodynamic improvement. To achieve
this, it is suggested to use absolute pressures of either
ankle pressure <50––70mmHg or toe pressure <30––50mmHg
or reduced supine forefoot TcPO2 <30––50mmHg.
Some points need to be discussed. First, the expression
“attributable to objectively proven PAOD” used in Recom-
mendation 73 is very important. Indeed, the association
of rest pain or trophic changes on the distal part of a
leg with PAOD does not mean ipso facto that PAOD is
in CLI stage, i.e. severe enough to explain the clinical
symptoms and/or signs presented by the patient. Second,
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raising the threshold of ankle pressure to 70mmHg does
not seem a good compromise in response to the criticisms
on ankle pressure mentioned above. It might have been a
better choice to favour toe pressure measurement instead
for the objective conﬁrmation of CLI in a given patient (see
the recommendations in section 7). Third, the new threshold
values used in this document for toe pressure are just below
the ranges found in patients with intermittent claudication.
For forefoot TcPO2, the suggested cut-off is even at the lower
limit of values found in patients without PAOD.
3.3. Trans-Atlantic Inter-Society Consensus (TASC)
Document on Management of Peripheral Arterial
Disease II (2007)13
In this document, the recommendations are presented in a
summarised version.
Recommendation 16 Clinical deﬁnition of critical limb
ischemia (CLI)
The term critical limb ischemia should be used for
all patients with chronic ischemic rest pain, ulcers
or gangrene attributable to objectively proven arterial
occlusive disease. The term CLI implies chronicity and is
to be distinguished from acute limb ischemia.
Recommendation 19 Diagnosis of critical limb ischemia (CLI)
CLI is a clinical diagnosis but should be supported by
objective tests.
Details and objective criteria can only be found in the full
text as follows: “Ischemic rest pain most commonly occurs
below an ankle pressure of 50mmHg or a toe pressure less
than 30mmHg. [. . . ] For patients with ulcers or gangrene,
the presence of CLI is suggested by an ankle pressure less
than 70mmHg or a toe systolic pressure less than 50mmHg.
(It is important to understand that there is not complete
consensus regarding the vascular haemodynamic parameters
required to make the diagnosis of CLI.)”
As summary recommendations are more often read than
the full text, only the items rest pain and ulcer or gangrene
remain highlighted over time, and the objective criteria
have lost their importance, being perceived as accessory.
This trend has unfortunately led to a major backward
step in the development of the concept of CLI, with
a return to initial deﬁnitions of 1950s based merely on
clinical ﬁndings, as in Fontaine stages III and IV. This is
highly regrettable, considering all the efforts undertaken
over the last two decades to standardise an objective and
reproducible deﬁnition of CLI.
3.4. General comments on the haemodynamic parameters
used to deﬁne CLI
After presenting the different deﬁnitions suggested for
CLI, it seems important to discuss some points concerning
the haemodynamic assessment methods used in these
deﬁnitions.
First, it should be emphasised that ankle systolic pressure
(expressed as an absolute value or as ABI) is not a highly
reliable parameter in patients with suspected CLI. Although
an ABI 0.40 or an ankle pressure 50mmHg (measured
in supine position or using the “pole test” method)16,17 is
consistent with a diagnosis of CLI, toe pressure measurement
should clearly be recommended for all patients with
suspected CLI.18,19 Indeed, ankle pressure measurement
is subject to erroneous results in patients with leg
artery calciﬁcation, mainly represented by patients with
diabetes or end-stage renal failure and in the very
old, the measured value reﬂecting arterial wall rigidity
rather than the actual perfusion pressure.19,20 If the
arteries are still partially compressible, falsely elevated
(and reassuring) pressure values are measured. In case of
incompressibility, no pressure result can be obtained. Lack
of compressibility is exceptionally an issue when measuring
toe pressure.
Then, methods providing functional information on tissue
perfusion and skin viability, such as forefoot TcPO2, are
still too seldom used mainly because of their limited
availability.21 When performed properly, forefoot TcPO2 has a
high prognostic value (see section 6.2 on risk stratiﬁcation).
Its use on a larger scale should therefore be strongly
encouraged in vascular clinics.
3.5. Chronic “subcritical” limb ischaemia
The expression “chronic subcritical limb ischaemia” was ﬁrst
introduced by Wolfe et al. to name a state of lower limb
ischaemia borderline to CLI as deﬁned in the 1991 European
consensus.22 It represents a subgroup of patients who do not
meet the 1991 CLI criteria or in whom severely reduced
ﬂow to the foot does not present as rest pain, ischaemic
ulceration, or ischaemic gangrene. Patients in this stage
of “transition” between exercise-induced ischaemia and
permanent critical ischaemia are nevertheless a subgroup
at risk that is important to identify.22,23 Although distal
blood ﬂow might be just sufﬁcient to maintain skin integrity
in these patients, it will probably not meet the needs of
the wound healing process, which requires a higher and
pulsatile ﬂow.
4. Epidemiology
4.1. Estimated incidence and prevalence of CLI
The precise assessment and comparison of epidemiologic
data on CLI is extremely difﬁcult –– almost impossible –– for
several reasons.
First, whereas identiﬁcation of PAOD based on an ABI <0.90
is fairly easy, identiﬁcation of CLI (rest pain and trophic
changes attributable to PAOD) needs an expertise not readily
available when evaluating large numbers of patients in the
setting of epidemiological studies.
Second, data are subject to major differences between
studies due to differences between deﬁnitions of CLI used
in these studies. Indeed, as already mentioned above,
CLI deﬁnition has evolved over time, but more importantly,
a strict deﬁnition including objective haemodynamic
parameters is not always used, and all patients with rest pain
or trophic lesions are sometimes included without conﬁrming
the severity and causative effect of arterial insufﬁciency,
therefore leading to higher rates of “CLI”.
Third, the actual statistical data on incidence and
prevalence of CLI are often inferred from two indirect
markers: the overall incidence of major amputations
(assuming that about 25% of CLI patients will undergo
amputation) and the natural history of PAOD.24 Both are
debatable. Indeed, depending on the country, 70––90% of
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amputations are considered to have a vascular cause,
even though many amputations are still performed without
any vascular workup.25 Then, the natural history of
PAOD does not follow a standardised progression through
different clinical stages. It is estimated that 5––10% of
patients with asymptomatic PAOD or claudication will
progress to CLI at 5 years and that 1––3% of patients
with PAOD are in CLI stage at initial presentation.13 This
latter group is often represented by older and sedentary
patients who have limited mobility (and therefore do
not claudicate), patients with sensory neuropathy who
have impaired pain sensation, and patients with additional
medical conditions reducing peripheral perfusion (such
as cardiac failure), who present directly with advanced
disease. Studies suggest that half of CLI patients do
not present any PAOD symptoms 6 months prior to the
onset of CLI.26
Nevertheless, the incidence of CLI derived from natural
history of PAOD and major amputation rates has been
estimated to be approximately 500––1000 per million
per year in a European or North American population
(150,000 cases per year for the USA).13
In contrast, the incidence of CLI based on large
prospective population studies is 220 new cases per million
per year in the general population.27 The prevalence of
CLI in the population aged 60––90 years is estimated at 1%
(0.5––1.2%), but ﬁgures vary widely between population-
based studies and vascular registries. For instance, in
2004 in Sweden, the prevalence of CLI was estimated
to be at least 15,000 patients, but the number of
vascular interventions for CLI was only 1700 for the same
period.28 The reported gender differences in CLI prevalence
vary between studies. In series of patients with CLI,
the men to women ratio is around 3:1.13 However,
in population-based epidemiological studies, age-adjusted
prevalence of CLI is equal in men and women after
50 years, a ﬁnding that correlates with epidemiological
studies on prevalence of PAOD based on ABI measure-
ment.28––30
4.2. Risk factors for CLI
In the vast majority of cases, CLI is caused by multi-level
occlusive atherosclerotic disease. Consequently, CLI patients
share the same traditional risk factors as patients with
atherosclerosis in other territories. Moreover, as CLI is
an advanced stage of PAOD occurring late in the course
of patients’ atherosclerotic disease, concomitant severe
cerebrovascular (CVD) and coronary artery diseases (CAD)
are more frequent than in patients with claudication.
Indeed, 50––75% of CLI patients have associated CVD and
about 20% have associated CAD.
Among cardiovascular risk factors, some are more strongly
associated with progression to CLI: threefold increase in
the risk of developing CLI in the case of a long history
of chronic heavy smoking and fourfold in the case of
diabetes.10,13 The risk of developing CLI rises proportionally
to the number of cigarettes smoked.31 The duration of
smoking cessation needed to return to baseline risk is
however not known, but is usually considered to be around
2 years in patients at risk of cardiovascular diseases.
Diabetes may be known and treated or unknown and
revealed by the CLI episode. In some countries in which
the care of diabetic patients is less well established and
generalised, CLI incidence may be 10 to 20 times higher
in diabetic compared to non-diabetic patients. The true
impact of diabetes is, however, difﬁcult to assess, and the
proportion of diabetic patients varies dramatically between
published series of CLI, ranging from 35% to 80%. As already
discussed in the preceding section, diagnosing CLI in diabetic
patients is particularly challenging due to the presence of
numerous confounding factors, such as sensory neuropathy
and frequent infectious complications that can possibly lead
to ulceration and gangrene even in the absence of any PAOD.
In contrast, calciﬁcation of leg arteries (Monckeberg disease)
may cause an overestimation of ankle pressure, leading to
falsely reassuring results.
Increasing age is another risk factor for CLI. The
mean age of CLI patients is higher than that of non-
CLI patients (about 75 years) but the range is wide (35––
100 years). In the elderly, the CLI event often occurs
in the setting of arterial and non-arterial poly-morbid
conditions. Chronic renal failure is also associated with
increased risk of PAOD and CLI, as well as increased
cardiovascular mortality.32 As in diabetics, diagnosis of CLI
can be difﬁcult in the very old and in patients with chronic
renal failure due to frequent calciﬁcation of leg arteries and
sensory neuropathy.33,34 African-American ethnicity may also
represent a risk factor independent from other traditional
atherosclerotic risk factors, based on data concerning PAOD,
but there are no data speciﬁc to CLI.35
Some other factors can cause or lead to progression
of CLI without being actual risk factors. Atheroembolic
(ulcerated plaques, popliteal aneurysms) or thromboembolic
(mainly cardioembolic) disease, in situ arterial thrombosis
due to congenital or acquired hypercoagulable states,
vasculitis, thromboangiitis obliterans, popliteal entrapment,
or trauma can all lead to compromised distal perfusion of
the extremity with the potential progression to a clinical
picture of CLI. Generally, arterial insufﬁciency and CLI
secondary to these diseases present as a more rapidly
progressive disease than atherosclerotic PAOD. Although
rare, some anatomical variations of leg arteries can also
lead more readily to CLI in case of occlusive disease,
due to altered blood-ﬂow distribution to foot arteries.
Finally, some associated conditions can represent aggra-
vating and/or confounding factors, particularly peripheral
neuropathy.
In summary, in spite of the limitations of epidemiological
data, partly related to varying deﬁnitions of CLI, one thing
is beyond doubt: the total cost of CLI is considerable!
And as for venous ulcers and chronic venous disorders, a
small percentage of cases cost more than all others due to
high rates of re-interventions, amputations, comorbidities
and disability. In the presence of an ageing population and
increasing worldwide prevalence of diabetes, an increase in
CLI incidence and prevalence is to be expected over the
future decades, making it a major public health issue.
5. Clinical presentation of CLI
As mentioned above, CLI refers to the extreme stage
of chronic arterial insufﬁciency of a lower extremity
in which distal blood ﬂow and microcirculatory function
(vasomotor adaptation, capillary recruitment) are severely
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compromised,36 resulting in a clinical picture including
ischaemic rest pain, ischaemic ulcer and/or gangrene as well
as other clinical signs related to forefoot haemodynamic and
trophic changes described in this section.
5.1. Ischaemic rest pain
According to the main guidelines and the 1991 European
consensus,11 ischaemic rest pain must be named as such
if it corresponds to the description by Cranley: “ischemic
rest pain is pain that occurs in the toes or in the
area of the metatarsal heads. Occasionally, it occurs in
the foot proximal to the metatarsal heads. Elevation of
the limb above or at the horizontal position aggravates
the pain and pendency, to some degree at least, brings
relief”.37 In more than 90% of cases, the toes are involved.
Three degrees can be described. First, the pain starts at
primo-decubitus and declines quickly –– the patient can
thus stay supine; of note, the patient can experience
numbness or tingling instead of pain. Second, the patient
needs to dangle his leg to relieve the pain. Third, the
patient has to remain seated to relieve the pain. In
second and third degrees, dependent foot oedema develops,
worsening the ischaemia because increased tissue pressure
exceeds capillary pressure. It is important to bear in
mind that rest pain depends on pain perception, which
can be reduced or abolished in the case of sensory
neuropathy (secondary to diabetes, ageing, or to ischaemia
itself).
5.2. Ischaemic ulcer and gangrene
Ulcerations occurring in the context of severe ischaemia
related to PAOD are located at the limb extremity, involving
the toes and foot (especially on pressure areas like the heel
or the ﬁrst and ﬁfth metatarsal heads). Clinically, they have
an inactive edge, pale necrotic base or are covered with
ﬁbrinous material. Whereas ischaemic rest pain has a typical
and standardised presentation (in the absence of sensory
neuropathy), ischaemic ulcer and toe gangrene are much
more difﬁcult to identify as lesions clearly attributable to
end-stage PAOD.11,26––28 Schematically, three situations can
be encountered. First, arterial insufﬁciency is severe, and
the ischaemic skin lesion occurs spontaneously or after a
minor trauma. Second, arterial insufﬁciency is moderate
but severe enough to impair the healing process of any
skin lesion (skin ﬂow needed for wound healing is much
higher than skin ﬂow necessary for baseline nutritional
requirements of an intact skin). Third, PAOD is present, but
only as an associated condition, with no causal relationship
with skin lesions. Even in the presence of toe gangrene,
the potential morphological lesions of lower limb arteries
identiﬁed by imaging techniques may be innocent if
perfusion pressure remains well above threshold values
for critical ischaemia. This issue is particularly important
in diabetic foot lesions because of numerous potential
confounding factors, and the causative link between PAOD
and trophic changes should be documented with particular
attention in these patients.
As a general rule, all patients with ulcers or gangrene
of the extremity should ﬁrst be thoroughly examined
for other associated clinical signs suggestive of chronic
compromised blood ﬂow to the foot (see below). Then, an
objective quantiﬁcation and conﬁrmation of the severity
of foot ischaemia by distal pressure measurement and
microcirculatory assessment (mainly forefoot TcPO2) should
be performed. This indeed seems the only way to avoid
the simplifying equation “gangrene/ulcer = critical limb
ischaemia”.
5.3. Other clinical signs of CLI-related forefoot
haemodynamic changes
Other less well known signs of CLI can easily and rapidly be
assessed by simple inspection and palpation of the foot and
are highly informative.
Some of these signs are related to low residual perfusion
pressure and consequent vasomotor paralysis. Reﬁlling of the
foot’s superﬁcial veins after emptying with the physician’s
thumb and capillary reﬁlling time at forefoot level are
normally nearly instantaneous, but become more and more
prolonged as arterial insufﬁciency becomes more severe.
Also, hydrostatic pressure changes when elevating or letting
the foot in a dependent position induce the following colour
changes: rapid (<30 seconds) appearance of foot sole pallor
by elevating the limb at 60º above bed level (Buerger’s test),
and foot erythrocyanosis in dangling position (also called
dependent rubor).
Other signs already reﬂect trophic changes secondary
to chronic severe ischaemia: shrinking and atrophy of
the toe pulp or heel pad, with bone contact felt on
palpation.38,39
When present, these clinical signs are predictive of severe
arterial insufﬁciency (ABI <0.50, toe pressure <30mmHg,
forefoot TcPO2 <30mmHg in supine position; p < 0.01
[personal unpublished data]). On the contrary, absence of
these signs makes the diagnosis of CLI unlikely. Looking for
these clinical changes is thus an important part of the initial
assessment of clinical probability of CLI.40,41
The pole test, a variant of Buerger’s test, is yet another
useful clinical tool to evaluate ankle or toe pressure.16,17
It allows estimating a toe pressure <55––70mmHg and
ankle pressure <45mmHg, and is particularly useful when
calciﬁcation of leg arteries impairs accurate ankle pressure
measurement and a device for toe pressure measurement is
not available.
6. Natural history and prognosis
6.1. Natural history of CLI patients
CLI is a very severe medical condition with a high risk of
major amputation, disability and death. In a way, it behaves
like a malignant disease. In the consensus documents
discussed above, as well as in review articles, the natural
history of CLI patients is summarised as follows:
• At presentation: 20––25% of patients undergo primary
amputation, 50––60% have vascular reconstruction
(surgical and/or endovascular), and 25% are treated
medically.
• One year later: 20––25% of patients will have died,
25––30% will have had major amputation, 20% will
still be in CLI state, and 25% will be alive without
major amputation and free from signs and symptoms
of CLI.10,13
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Although these ﬁgures are always cited in the introduction
of articles published on CLI, they often do not correlate
with more recent publications on CLI patients’ outcome, for
at least two main reasons. First, the overall management
of cardiovascular patients has dramatically changed in
recent years, and an increasing proportion of patients
are offered “best medical treatment” and risk-factor
modiﬁcation counselling, which could of course partly
account for a better global prognosis of CLI patients.
However, there seems to be a second important reason
for the discordance between prognosis data derived
from original series compared to more recent series. As
discussed in previous sections, inclusion criteria of many
recent studies have been described as “Fontaine stage
III or IV” as if it was an equivalent of CLI, without any
haemodynamic criteria. Therefore, less severe patients (in
terms of systemic atherosclerotic disease) might have been
included in recent series, contributing to a better overall
prognosis.
The TAMARIS trial probably offers the most reliable recent
data on the natural history and prognosis of CLI.21 It included
patients with CLI deﬁned according to the TASC I document,
who were unsuitable for revascularisation as assessed by a
vascular surgeon. Patients were randomised to an angiogenic
treatment (NV1FGF) or placebo. From December 2007 to
July 2009, 525 patients were included in 171 hospitals in
30 countries. No patient was lost to follow-up. The primary
combined endpoint was time to major amputation of the
treated leg or death from any cause during the study
period of 12 months. Primary outcome was encountered
in 33% (95%CI: 27––39%) of patients in the placebo group
(major amputation or death 33%, major amputation 21%,
death 15%). Death was from a cardiovascular cause in 49%,
a non-cardiovascular cause in 41%, and unknown origin
in 10%.21
6.2. Risk stratiﬁcation
After establishing a precise diagnosis of CLI based on clinical
and haemodynamic criteria, which clearly helps evaluating
and comparing different treatment modalities (surgical
and/or endovascular strategies, angiogenic treatments,
conservative medical management, etc.) in terms of
outcome and cost-effectiveness, the next step is to
stratify local and general risk in order to better identify
which patients beneﬁt most from each management
strategy. A prediction model derived from the BASIL
study has been proposed to facilitate clinical decision-
making in patients with severe ischaemia.42 It mainly
illustrates the fact that this stage of advanced PAOD
is associated with high cardiovascular risk due to major
comorbidities.
There is a need for risk stratiﬁcation tools taking
into account quantitative assessment of the degree of
ischaemia. As with venous thromboembolism (VTE), we
may apply the following decision process: (1) clinical
probability assessment, (2) diagnostic validation, (3) risk
stratiﬁcation. A thorough assessment of the symptoms and
signs described above establishes the clinical probability
of CLI. Then, objective measurement of distal perfusion
pressure (toe pressure, pole test) is needed to conﬁrm
the diagnosis of CLI,43 with the role of additional vascular
imaging being mainly to deﬁne the actual treatment
strategy. Finally, the same haemodynamic measurements
used for diagnosis conﬁrmation can be used for risk
stratiﬁcation.
Nevertheless, the capability of distal pressure (ankle
pressure and even toe pressure) to predict amputation
risk is limited.7,44––46 Forefoot TcPO2, if measured according
to methodological rules (particularly avoiding areas of
thick or oedematous skin) is probably the best non-
invasive method for quantiﬁcation of ischaemia severity
and prognostic assessment.41 Forefoot TcPO2 may be
considered a marker of total distal run-off (arterial
and arteriolar run-off) and perfusion reserve. In the
setting of risk stratiﬁcation, different values have been
suggested, but almost all series are in agreement
with the following criteria: in case of supine forefoot
TcPO2 >35––40mmHg, local prognosis is fairly good even
with conservative management, and these patients can
therefore not be truly considered to have CLI; in case
of supine forefoot TcPO2 10––35mmHg, local prognosis is
intermediate; in case of supine forefoot TcPO2 10mmHg
(which corresponds to the 1991 European consensus
document’s recommendation for the diagnosis of CLI11),
local prognosis is very poor. Of note, further prognostic
stratiﬁcation of patients with low supine forefoot TcPO2
(<20mmHg) can be performed by testing perfusion reserve
in sitting position or under oxygen inhalation (oxygen
inhalation being more efﬁcient when performed in sitting
position).46,47
In a personal prospective series of 205 patients with CLI
deﬁned according to the 1991 European consensus with
supine forefoot TcPO2 10mmHg, all operated on (bypass
surgery and/or PTA) with a follow-up >1 year, the overall
rate of major amputation-free survival at 1 year was 50%.
It was 75% in case of TcPO2 improvement in sitting position
(to 40mmHg) and only 35% if TcPO2 remained <40mmHg in
sitting position.46
Data are insufﬁcient to give a grade A recommendation,
but seem enough to give a grade B recommendation for a
baseline risk stratiﬁcation scale (major amputation or death)
in four degrees, based on forefoot TcPO2 in addition to initial
careful clinical examination.
• Degree 1: 10mmHg < forefoot TcPO2 35mmHg in supine
position.
• Degree 2: forefoot TcPO2 10mmHg in supine position
but clear improvement (40mmHg) in sitting position or
under oxygen inhalation.
• Degree 3: forefoot TcPO2 10mmHg in supine position and
inadequate or no improvement (<30––40mmHg) in sitting
position or under oxygen inhalation.
• Degree 4: forefoot TcPO2 10mmHg in supine and in
sitting position and/or under oxygen inhalation (very poor
prognosis).
7. Conclusion and recommendations
As CLI prevalence is expected to increase over the future
decades and become a major public health issue, it is of
utmost importance to bear in mind some major key points
that help to characterise patients with precision in order to
assess and compare current or future treatment modalities.
These can be summarised as follows:
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Recommendations
(1) The expression chronic critical limb ischaemia (CLI)
deﬁnes the extreme stage of chronic arterial insuf-
ﬁciency of a lower limb in which stenosis and/or
occlusion of the arterial tree lower the downstream
perfusion pressure to such an extent that nutritional
ﬂow to tissues is severely compromised and does
not allow maintaining skin integrity or wound healing
without revascularisation. (Level 1a; Grade A)
(2) The presence of rest pain or a wound, ulcer
or toe gangrene on a lower limb with arterial
disease (PAOD) is not sufﬁcient to qualify as CLI.
They must be recognised as attributable to the
PAOD by combining speciﬁc clinical characteristics
of pain and/or skin lesions, as well as other signs
of severe chronic forefoot ischaemia, with objective
haemodynamic measurements. (Level 2b; Grade B)
(3) Ankle systolic pressure (absolute value or ABI) is not
a reliable parameter for CLI diagnosis. (Level 2b;
Grade B)
(4) Toe pressure measurement is more accurate and is
recommended in all patients with suspected CLI.
(Level 2b; Grade B)
(5) Assessment of distal tissue perfusion pressure by
forefoot TcPO2 measurement should be recommended
for diagnostic validation and prognostic stratiﬁcation,
at least in the setting of clinical trials. (Level 2b;
Grade B)
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